Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aytu BioScience Inc. (AYTU)

Add AYTU Price Alert      Hide Sticky   Hide Intro
Moderator: BioSpecialist
Search This Board: 
Last Post: 11/10/2017 7:25:53 PM - Followers: 14 - Board type: Free - Posts Today: 0

Ridiculous Market Cap of $16 M / Cash $11.8 M / 4 Marketed Products one of them called Natesto (hypogonadism) targeting $2 BILLION Market which has the potential to be the next market leader (please read below for more infos) Shares Out only 4.22 M . This low float stock should be valued at minimum $120-150 Million (~$30-35 per share ) right now for their marketed products .GL

Market Cap : $16 Million
Cash $11.8 Million
Price $4

Shares Out 4.22 Million


Fact Sheet

Marketed Products:

•Natesto–testosterone nasal gel indicated for hypogonadism ($2 billion market in the U.S., 13 million men diagnosed with hypogonadism (low testosterone)

•MiOXSYS–in vitro device for male infertility ($825 million International market ,30 million men impacted in U.S.)

•Fiera–pre-intimacy device to increase sexual desire and arousal in women (53 million women in the U.S. with sexual concerns)

•ProstaScint–imaging agent for prostate cancer

Don't you guys think that Aytu BioSciences Natesto, FDA approved, nasal TRT is far superior to Lipocines Tlando?

Aytu BioScience (AYTU) Stock: Why This Thing Can Grow Legs!

The Doors To Massive Potential Have Swung Wide Open

As if there already wasn't massive potential surrounding NATESTO, the flood gates may open soon as the competition has largely been cleared off of the playing field. That happened relatively recently when Acrux and Eli Lilly ended their relationship surrounding the testosterone product known as Axiron, a TRT applied under the arm.

It all started back in 2010 when Acrux and Eli Lilly entered into a license agreement surrounding Axiron. As a result of the deal, there would be $335 million plus potential royalties up for grabs. However, early this month, in fact on September 6th, it was announced that both companies have reached an agreement to terminate the license agreement.

While this may not seem like a big deal at first glance, it's massive. You see, Axiron was one of the only competing drugs that was marketed on a large scale. However, for this marketing to take place, it had to happen with the help of Eli Lilly. Since the relationship has been split, the marketing is no longer in place. As a result, AYTU has an open playing field with NATESTO, giving it the opportunity to tackle the market in a big way.

NATESTO Is Black Box Free

While there are many advantages that we see in NATESTO over other testosterone replacement therapies, there's one key advantage that really strikes us. That is the fact that the product is the only TRT (Testosterone Replacement Therapy) currently on the market that's not only effective, but comes with no black box warnings.

For those of you who don't know, black box warnings are among the strictest warnings that the FDA imposes on labeling of prescription drugs. These warnings are only used when there is reasonable evidence of an association of a serious hazard with the drug in question. While other TRTs on the market have various black box warnings associated with the risk of a man transferring testosterone gel to his female partner or child, NATESTO is black box warning free; making it one of the safest, if not the safest option for testosterone replacement.

The Bottom Line

The bottom line here is that AYTU has a tremendous opportunity and through this opportunity, poses a potentially incredible opportunity for investors themselves. Looking at NATESTO, it's clear that not only is this drug the safest option, it is likely to become the first option. With the sales force nearing the ability to hit the ground running and an incredible management team behind them, I believe that 2018 will be the year for AYTU; and we haven't even touched on Fiera or Mioxys yet.... those are topics for another day!

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AYTU News: Quarterly Report (10-q) 11/09/2017 04:11:54 PM
AYTU News: Current Report Filing (8-k) 11/09/2017 04:05:41 PM
AYTU News: Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET 11/09/2017 04:01:00 PM
AYTU News: Aytu BioScience Receives Market Approval from the Australian Therapeutic Goods Administration for the MiOXSYS® System for Ma... 11/07/2017 08:05:00 AM
AYTU News: Aytu BioScience to Report Fiscal First Quarter 2018 Results and Business Update 11/02/2017 08:05:00 AM
#99   An article out today on AYTU: fatcat2 11/10/17 07:25:53 PM
#98   AYTU - Fiscal First Quarter 2018 Business Update fatcat2 11/09/17 05:21:52 PM
#97   AYTU is a long term Buy & Hold. fatcat2 10/31/17 01:28:22 PM
#96   Aytu BioScience Provides Quarterly Update on the Natesto® Skalar 10/26/17 02:58:31 PM
#95   In a statement, Josh Disbrow, CEO at Aytu fatcat2 10/26/17 01:12:37 PM
#94   In a statement, Josh Disbrow, CEO at Aytu fatcat2 10/26/17 01:12:37 PM
#93   Thanks. I went to SEC website couldn't find it. fatcat2 10/25/17 10:23:23 AM
#92   Filed with EDGAR today. willlbone 10/25/17 10:15:06 AM
#91   Have you found any news? I sure would fatcat2 10/25/17 10:07:25 AM
#90   Are they dumping 6 million shares willlbone 10/25/17 10:00:53 AM
#89   Any reason for this dump? fatcat2 10/25/17 09:52:51 AM
#88   READ: fatcat2 10/24/17 04:36:12 PM
#87   I thought AYTU would've closed higher on its fatcat2 10/20/17 04:27:04 PM
#86   AYTU moved from the OTC to the Nasdaq: Renee 10/20/17 08:15:33 AM
#85   AYTU is going to Nasdaq on October 20, fatcat2 10/18/17 09:34:41 AM
#84   I'm planning to sell when it's in the serious38 10/17/17 04:25:56 PM
#83   nice jump BioSpecialist 10/17/17 12:09:02 PM
#82   Alone the 10 largest shareholders owns almost half BioSpecialist 10/13/17 03:15:29 PM
#81   This extreme low float stock can hit $10 BioSpecialist 10/12/17 03:04:02 PM
#80   this could hit $10 in no time because BioSpecialist 10/12/17 02:39:35 PM
#79   I load up every chance I get. I'm fatcat2 10/12/17 12:51:57 PM
#78   thats the next one that will go through BioSpecialist 10/12/17 08:42:14 AM
#77   AYTU-DD = Market Cap $18 M / Cash BioSpecialist 10/11/17 10:27:46 AM
#76 fatcat2 10/03/17 03:14:02 PM
#75   Once this starts flying, it will fly. fatcat2 10/03/17 03:07:36 PM
#74   NEWS!!! - C-Money365 10/03/17 11:10:38 AM
#73   That's great. fatcat2 09/28/17 09:38:27 AM
#72 Avispa 09/28/17 08:34:20 AM
#71   After yesterday good report AYTUD should have popped. fatcat2 09/27/17 10:30:15 AM
#70   PR News: fatcat2 09/26/17 05:11:56 PM
#69   The Testosterone Replacement sector is a ho sector. fatcat2 09/18/17 11:40:44 AM
#68   AYTU one for 20 reverse split: Renee 08/25/17 07:44:57 PM
#67   Financial report is Thursday. Really hoping to see Jaynes19 05/08/17 11:03:50 AM
#66   I see a ton of potential here as Jaynes19 03/15/17 08:58:09 PM
#65   Not wanting to sound like a crazy pumper WallStPirate 03/08/17 07:54:41 AM
#64   Good article about Aytu's potential. Jaynes19 02/24/17 09:11:18 PM
#63   Still plenty of time to buy. Probably see Jaynes19 02/09/17 09:42:25 PM
#62   Should have bought some! tjguy 02/09/17 08:09:38 PM
#61   great numbers!!!! and Natesto ramping quicker than expected microcaptrdr24 02/09/17 06:04:45 PM
#60   Thanks for the info. Pretty curious to see Jaynes19 02/09/17 10:20:59 AM
#59   earnings call tonight could give this a push microcaptrdr24 02/09/17 09:39:44 AM
#58   It's on my "Wanted List", but waiting for tjguy 02/09/17 01:59:32 AM
#57   I met the CEO at LD Micro in microcaptrdr24 02/08/17 01:45:59 PM
#56   Has anyone heard anything positive recently? A lot Jaynes19 01/26/17 10:40:30 PM
#55   GO AYTU seven-up 12/06/16 02:30:37 PM
#54   Zertane is being x'd from the list because zc182 11/24/16 09:48:38 PM
#53   Need a run seven-up 10/17/16 12:27:17 PM
#52   There might be an undiscovered market for Natesto. FarmaZutical 10/06/16 07:10:29 AM
#51   I'm a long time Trimel / Acerus investor FarmaZutical 09/04/16 03:51:34 PM
#50   Has any analyst suggested the percentage of the Eitzenschild 09/04/16 02:15:04 PM